Skip to main content

Table 1 Characteristics of RS3PE patients with or without malignancy

From: bFGF could be a biomarker of malignancy in RS3PE syndrome: an ambispective single-center cohort analysis of 51 patients

  Overall (n = 51) RS3PE with malignancy (n = 8) RS3PE without malignancy (n = 40) P
Age (years) 73.39±9.18 75.00±11.07 73.50±8.51 0.667
Age of onset (years) 73.24±9.23 74.5±11.30 73.4±8.53 0.754
Gender (M/F) 28/23 5/3 21/19 0.710
Pitting edema of hands (n, %) 45 (88.2) 7 (87.5) 35 (87.5) 1
Bilateral (n, %) 42 (93.3) 5 (71.4) 34 (97.1) 0.067
Weight loss (n, %) 18 (35.3) 5 (62.5) 12 (30) 0.112
CEA > 4.7 ng/mL 0a / / /
AFP > 7ng/mL 1 (2.6)a 1 (14.3)c 0b 0.152
CA19-9 > 39U/mL 2 (5.1)a 0c 2 (5.1)b 1
CYFRA21-1 >3.3 ng/mL 3 (6.5)a 1 (14.3)c 2 (5.1)b 0.398
NSE >16.3 ng/mL 8 (17.4)a 2 (28.6)c 6 (18.2)b 0.587
C reactive protein (mg/L) 43.9 (22.8, 82.0) 35.9 (12.0, 91.0) 45.7 (26.4, 84.9) 0.674
Erythrocyte sedimentation rate (mm/h) 55.37±34.12 48.88±29.00 56.85±35.81 0.558
Immunoglobulin A (g/L) 3.05 (1.62, 3.73) 2.71 (1.18, 3.66) 3.13 (1.62, 4.04) 0.734
Immunoglobulin G (g/L) 12.42±4.74 12.56±5.24 12.32±4.81 0.900
Immunoglobulin M (g/L) 0.71 (0.50, 1.09) 0.68 (0.50, 1.39) 0.71 (0.47, 1.12) 0.968
Complement 3 (g/L) 1.04 (0.87, 1.28) 1.03 (0.79, 1.16) 1.05 (0.88, 1.29) 0.422
Complement 4 (g/L) 0.23±0.09 0.25±0.04 0.24±0/09 0.722
ANA≥1:80 (n, %) 6 (11.8) 0 6 (15) 0.571
Anti-Ro-52 (n, %) 5 (9.8) 1 (12.5) 4 (10) 1
Initial prednisolone dose 15 (15, 30) 15 (10, 30) 15 (15, 27.5) 0.946
Fast response to prednisolone (n, %) 44 (89.8) 3 (42.8)d 38 (97.4) 0.001*
  1. Values displayed as n (%), mean ±standard deviation, or median (P25, P75) according to their features of the distribution
  2. Note: RS3PE remitting seronegative symmetrical synovitis with pitting edema, ANA anti-nuclear antibody, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, CA19-9 carbohydrate antigen 19-9, CYFRA21-1 cytokeratin 19 fragment, NSE neuroenolase
  3. *P<0.05, a significant difference between RS3PE patients with and without malignancy
  4. aFive patients did not have the data of serum tumor markers
  5. bTwo patients did not have the data of serum tumor markers
  6. cOne patient did not have the data of serum tumor markers
  7. dOne patient did not receive glucocorticoids